A prospective, controlled, and randomized clinical study was carried out with the purpose of evaluating the influence of somatostatin in the evolution of acute pancreatitis. One hundred patients were randomly divided into two groups, a control group (n= 50 patients) and a somatostatin group (n= 50 patients to whom a dosage of 250 μg/h was administered for 48 h following a bolus of 250 μg at the beginning of therapy). The two groups were homogenous in age, sex, etiology, and severity of clinical picture (on admission). The following parameters were compared in the two group
展开▼
